Eflornithine/sulindac: Completed Phase III enrollment

Cancer Prevention completed enrollment of 166 FAP patients in a double-blind, placebo-controlled, international Phase III trial comparing

Read the full 179 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE